We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low priced biotech stocks to buy now.

Is Now the Time to Buy Biotech Stocks?

On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations in the sector may present buying opportunities once the uncertainty clears.

Talking about the broader impact of tariffs on the biotech sector, he said that the estimated tariff rate would be around 50%, while the negative EPS impact would be around -4-5%. According to Yee, the sector is facing several challenges that have caused significant pressure and anxiety among biotech investors. One of them is definitely sector-specific tariffs. The 50% estimation is a manageable impact for many of the biotech companies, but there are also other challenges being floated. Another factor is the most favored nations that could drop drug prices by as much as 40% to 50%, making it a related impact. Assuming all these impacts are going into place, there are definitely uncertain downside risks to the model.

However, the takeaway is that many of these stocks are down more than 20-30% and, in fact, are trading at a decade-low P/E multiple. Therefore, while these uncertainties may be out there over the next few weeks or months, the stocks are expected to move higher after that. If we look back at some other stocks with tariffs, many are obviously higher off the bottoms. They have thus fallen to an attractive valuation, which is why there might be an opportunity to buy them.

READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds.

Does the US Pay More For Drugs Than Other Countries?

Shedding light on the most favored nation policy, Yee said it is not new. It is also not a new concept that the US, on average, pays around 40% to 50% more for drugs as compared to the basket of other, say, five to ten major developed nations. The country also gets its drugs faster, and is the home of innovation.

Many of the pharmaceutical company executives over the past few weeks pointed out that most of those countries are also facing downside issues because of R&D investments, getting the drugs years later, and obviously, the countries aren’t benefiting from access to any of these drugs. However, the United States government does negotiate 15-20 drugs per year and will be doing that for the next decade.

Our Methodology

We sifted through stock screeners, financial media reports, and ETFs to compile a list of 50 low-priced biotech stocks and then chose the top 10 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is ordered in ascending order of hedge fund sentiment.

Note: The data was recorded on May 9.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (see more details here).

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Stock Price: $5.98

Number of Hedge Fund Holders: 40

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is the fourth-best low-priced biotech stock to buy now. The company discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

On May 2, Leerink Partners analyst Joseph Schwartz reiterated their bullish stance on Amicus Therapeutics, Inc. (NASDAQ:FOLD), giving a Buy rating due to its growth potential and strategic positioning. The company recently announced a licensing agreement for DMX-200 to treat focal segmental glomerulosclerosis (FSGS), which has no FDA-approved therapies.

The analyst is bullish on the stock because of this strategic effort to capitalize on the regulatory advancements in the FSGS space. Since there are around 15,000 to 30,000 patients suffering from the condition in the United States, this move presents a significant market opportunity for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

The agreement’s financial terms include a $30 million upfront payment and up to $560 million in milestone payments, highlighting a well-structured yield with the potential to produce considerable returns, supporting the buy rating. Analysts are thus bullish on the stock, and its median price target of $5.98 implies an upside of 167.56% from current levels.

Overall, FOLD ranks 4th on our list of the best low priced biotech stocks to buy now. While we acknowledge the potential for FOLD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than FOLD but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.